Compare Enveric Biosciences Inc (ENVB) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Palo Alto Networks Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while Palo Alto Networks Inc trades at $418.59 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 48788.2× Enveric Biosciences Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Palo Alto Networks Inc for 82 Days on average.
| ENVB | PANW | |
|---|---|---|
Market Cap | $6.80M | $331.76B |
Volume | 64,867 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $10.80 | $419.91 |
52-Week Low | $1.27 | $141.67 |
Typical Hold Time | 14 Days | 82 Days |
Enterprise Value | -$1.49M | $331.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.48, down 1.0% today, with a bearish technical signal from moving averages but neutral oscillators. The company shows negative profitability with ROE at -235.48% and ROA at -193.53%, though it has beaten EPS expectations for four consecutive quarters. Recent developments include patent allowances for non-hallucinogenic therapeutics and positive preclinical data for EB-003.
While analyst consensus is 75% buy with no sell ratings, fundamental weaknesses in revenue generation and negative cash flow from operations pose significant risks. The stock's appeal hinges on clinical progress and regulatory milestones, making it suitable for risk-tolerant investors betting on biotech innovation amid high operational and financial volatility.
Palo Alto Networks (PANW) trades at $418.78, up 3.3% with strong technical momentum near 52-week highs. The stock shows bullish moving averages and has consistently beaten earnings estimates in recent quarters. Revenue growth remains robust at $9.22B for 2025, though valuation metrics appear elevated with P/E at 1,013.93 and P/S at 26.99. The company's platformization strategy and AI security services are driving investor optimism.
Outlook remains positive with 72% analyst buy ratings and $398.70 consensus target, though premium valuation and rising costs present risks. AI cybersecurity demand creates growth opportunities, but execution on large customer deals and margin sustainability will be critical for continued upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
